Our client wanted to evaluate the potential of two treatments which would offer efficacy and side effects similar to those of biologics in atopic dermatitis.
They wanted to understand more about the market landscape and how advanced treatments fit into the treatment algorithm when they are launched, as well as the potential drivers and barriers to uptake of these treatments.
We utilized a quantitative online methodology to answer the client objectives, with the sample consisting of dermatologists.
To calibrate the data, we also asked respondents to provide expected prescribing share using best case and worst-case scenarios and also likelihood to prescribe the base case products.
Provided our client with a report that gave both an overview of the current market and the impact of new advanced treatment launches in the future. For the future market we used the conjoint results and future market share allocation exercises to model likely market share for the two products, including the scenarios where both treatments were available and also if only one of the treatments were available.
We provided an excel simulator which enabled them to view the expected market share and how it varied when certain attributes were changed (based on the pre-defined list of attributes/levels from the conjoint exercise). The client also received an overview stating the impact of each attribute on treatment decisions and also which levels within each attribute had greater impact. Finally, we were able to also identify the likely source of business for the future products. The outputs showed the client the likely uptake of their product across various scenarios to help inform future strategy for the brands.
Jump to a slide with the slide dots.
Our research experts investigate how a study design which better reflects real-world choices can produce a more realistic model for the future market.
Read moreAn interactive collection of case studies that outline how the views of patients, payers and physicians (and linked-choice modeling) can help you.
Read moreRapport is our monthly newsletter where we share our latest expertise and experience.